Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers

Blood

Volumn 98, Issue 1, 2001, Pages 224-230

  De Carvalho Bittencourt, Marcelo ^a,b,c   Perruche, Sylvain ^a,b,c   Contassot, Emmanuel ^a,b,c   Fresnay, Stéphanie ^a,b,c   Baron, Marie Hélène ^a,b,c   Angonin, Régis ^a,b,c   Aubin, François ^a,b,c   Hervé, Patrick ^a,b,c   Tiberghien, Pierre ^a,b,c   Saas, Philippe ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^d ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; LIPOCORTIN 5; MONOCLONAL ANTIBODY;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; FLOW CYTOMETRY; GAMMA IRRADIATION; GRAFT VERSUS HOST REACTION; LEUKOCYTE; LYMPHOCYTE DEPLETION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; ULTRAVIOLET IRRADIATION;

EID: 0035412373     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.1.224     Document Type: Article

References (39)

1. Petersdorf EW, Mickelson EM, Anasetti C, Martin PJ, Woolfrey AE, Hansen JA. Effect of HLA mismatches on the outcome of hematopoietic transplants. Curr Opin Immunol. 1999;11:521-526.
2. Ferrara JL, Cooke KR, Pan L, Krenger W. The immunopathophysiology of acute graft-versus-host-disease. Stem Cells. 1996;14:473-489.
3. Martin PJ, Kerman N. T cell depletion for GvHD prevention in humans. In: Burakoff S, Deeg HJ, Ferrara JL, Atkinson K, eds. Graft Versus Host Disease: Research and Clinical Management. New York, NY: Marcel Dekker; 1990:371-387.
4. Montagna D, Yvon E, Calcaterra V, et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood. 1999;93:3550-3557.
5. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999;340:1704-1714.
6. De Carvalho Bittencourt M, Tiberghien P, Saas P. Transplantation of anergic histoincompatible bone marrow allografts [letter]. N Engl J Med. 1999;341:1081-1082.
7. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells [letter]. Nature. 1997;390:350-351.
8. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998;101:890-898.
9. Freire-de-Lima CG, Nascimento DO, Soares MB, et al. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature. 2000;403:199-203.
10. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity. 1996;5:7-16.
11. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med. 2000;191:411-416.
12. Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med. 2000;6:464-469.
13. Contassot E, Ferrand C, Angonin R, et al. Ganciclovir-sensitive acute graft-versus-host disease in mice receiving herpes simplex virus-thymidine kinase-expressing donor T cells in a bone marrow transplantation setting. Transplantation. 2000;69:503-508.
14. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantifies of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77-92.
15. Mor F, Cohen IR. IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis: correlation with induction of Bcl-2. J Immunol. 1996;156:515-522.
16. + helper T cells: a model for the long-term survival of memory cells. J Immunol. 1996;156:1764-1771.
17. Booker JK, Reap EA, Cohen PL. Expression and function of Fas on cells damaged by gamma-irradiation in B6 and B6/Ipr mice. J Immunol. 1998;161:4536-4541.
18. Waller EK, Ship AM, Mittelstaedt S, et al. Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease. Blood. 1999;94:3222-3233.
19. Ring GH, Saleem S, Dai Z, et al. Interferongamma is necessary for initiating the acute rejection of major histocompatibility complex class It disparate skin allografts. Transplantation. 1999;67:1362-1365.
20. Truitt RL, Atasoylu AA. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation. Blood. 1991;77:2515-2523.
21. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204-3213.
22. Asiedu C, Meng Y, Wang W, et al. Immunoregulatory role of CD8alpha in the veto effect. Transplantation. 1999;67:372-380.
23. Martin PJ. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism. Blood. 1996;88:962-969.
24. Fink PJ, Shimonkevitz RP, Bevan MJ. Veto cells. Annu Rev Immunol. 1988;6:115-137.
25. Brown SB, Savill J. Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. J Immunol. 1999;162:480-485.
26. Gao Y, Herndon JM, Zhang H, Griffith TS, Ferguson TA. Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis. J Exp Med. 1998;188:887-896.
27. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol. 1993;11:165-190.
28. Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol. 1997;61:375-380.
29. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86-89.
30. Finkelman FD, Lees A, Birnbaum R, Gause WC, Morris SC. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol. 1996;157:1406-1414.
31. + T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med. 1998;187:1555-1564.
32. Thomson AW, Lu L. Dendritic cells as regulators of immune reactivity: implications for transplantation. Transplantation. 1999;68:1-8.
33. Huang FP, Platt N, Wykes M, et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med. 2000;191:435-444.
34. Sallusto F, Lanzavecchia A. Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. J Exp Med. 1999;189:611-614.
35. Magee CC, Sayegh MH. Peptide-mediated immunosuppression. Curr Opin Immunol. 1997;9:669-675.
36. Murphy B, Magee CC, Alexander SI, et al. Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis. J Clin Invest. 1999;103:859-867.
37. Nikolic B, Sykes M. Bone marrow chimerism and transplantation tolerance. Curr Opin Immunol. 1997;5:634-640.
38. Platt JL. Tolerance by transplantation: how much is enough, how much is too much? J Clin Invest. 1999;104:227-228.
39. Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med. 1998;188:387-392.